SwePub
Sök i LIBRIS databas

  Utökad sökning

L773:2058 5225 OR L773:2058 1742
 

Sökning: L773:2058 5225 OR L773:2058 1742 > (2019) > Cardiovascular even...

Cardiovascular event rates in a high atherosclerotic cardiovascular disease risk population : estimates from Swedish population-based register data

Lindh, Maria (författare)
Quantify Res, Hantverkargatan 8, S-11221 Stockholm, Sweden
Banefelt, Jonas (författare)
Quantify Res, Hantverkargatan 8, S-11221 Stockholm, Sweden
Fox, Kathleen M. (författare)
Strateg Healthcare Solut LLC, 133 Cottonwood Creek Lane, Aiken, SC 29803 USA
visa fler...
Hallberg, Sara (författare)
Quantify Res, Hantverkargatan 8, S-11221 Stockholm, Sweden
Tai, Ming-Hui (författare)
Dept Global Hlth Econ, One Amgen Ctr Dr, Thousand Oaks, CA 91320 USA
Eriksson, Mats (författare)
Karolinska Institutet
Villa, Guillermo (författare)
AMGEN Europe GmbH, Dept Global Hlth Econ, Suurstoffi 22,POB 94, CH-6343 Rotkreuz, Switzerland
Svensson, Maria K. (författare)
Uppsala universitet,Klinisk diabetologi och metabolism
Qian, Yi (författare)
Dept Global Hlth Econ, One Amgen Ctr Dr, Thousand Oaks, CA 91320 USA
visa färre...
 (creator_code:org_t)
2019-01-12
2019
Engelska.
Ingår i: European Heart Journal - Quality of Care and Clinical Outcomes. - : OXFORD UNIV PRESS. - 2058-5225 .- 2058-1742. ; 5:3, s. 225-232
  • Tidskriftsartikel (refereegranskat)
Abstract Ämnesord
Stäng  
  • Aims: This study aimed to estimate the rate of cardiovascular (CV) events in the real world in patients at high risk of recurrent CV events similar to the FOURIER trial population.Methods and results: A retrospective population-based cohort study was conducted using Swedish national registers from 1 July 2001 to 31 December 2015. Patients in the atherosclerotic cardiovascular disease (ASCVD) prevalent cohort met the FOURIER-like inclusion criteria, including treatment with high/moderate-intensity statins, on 1 July 2006. Additionally, two cohorts defined by diagnosis of incident ischaemic stroke (IS) and incident myocardial infarction (MI), meeting the FOURIER-like inclusion criteria were followed from date of diagnosis. Event rates were calculated for the hard major adverse cardiovascular events (MACE) composite: MI, IS, and CV death; and the ASCVD composite: MI, IS, unstable angina, coronary revascularization, and CV death. Approximately half of patients experienced a CV event (ASCVD composite) during follow-up. The MACE composite rates/100 person-years were 6.3, 11.9, and 12.3 in the ASCVD prevalent (n = 54 992), MI incident (n = 45 895), and IS incident (n = 36 134) cohorts, respectively. The ASCVD composite rates/100 person-years were 7.0, 21.7, and 12.9 in the ASCVD prevalent, MI incident, and IS incident cohorts, respectively. The multiple-event MACE composite rates/100 person-years were 8.5 (ASCVD prevalent cohort), 15.4 (MI incident cohort), and 14.4 (IS incident cohort).Conclusion: In this real-world setting, CV event rates were high in all studied cohorts. In particular, the MACE composite rates were two to three times higher than in the FOURIER clinical trial, indicating a substantial disease burden despite treatment with moderate or high-intensity statins.

Ämnesord

MEDICIN OCH HÄLSOVETENSKAP  -- Klinisk medicin -- Kardiologi (hsv//swe)
MEDICAL AND HEALTH SCIENCES  -- Clinical Medicine -- Cardiac and Cardiovascular Systems (hsv//eng)

Nyckelord

Cardiovascular outcomes
Cardiovascular event rates
Secondary prevention
ASCVD

Publikations- och innehållstyp

ref (ämneskategori)
art (ämneskategori)

Hitta via bibliotek

Till lärosätets databas

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy